Osteoporosis drug needs safety review

An osteoporosis expert is urging the Therapeutic Goods Administration to review the safety of strontium, after European regulators imposed restrictions on the drug because of increased cardiac risks.

The European Medicines Agency (EMA) recommended last week that strontium (Protos) be restricted to only severe cases of osteoporosis, in men and women alike.

Additional measures, including restrictions on the use of strontium